Handelsavisen
prelaunch
Companies Healthcare HROW.O
HR
HROW.O NASDAQ Pharmaceuticals

Hrow.O

$39,09
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,5B USD
P/E
EV / Rev
6,1x
Div yield
Op margin
4,4 %
ROE
-28,5 %
Net margin
-5,6 %
Debt / equity
4,77
Beta
52w range
Volume
Day range
Prev close
$39,32
Open
$37,46
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Harrow Inc. operates in the Health Care sector, specifically within the Pharmaceuticals industry, generating revenue through its disclosed business activities.

Business. Harrow Inc. operates in the Health Care sector, specifically within the Pharmaceuticals industry, generating revenue through its disclosed business activities.

Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target65,57

Analyst recommendations

8 analysts · consensus Buy
Buy8
Hold0
Sell0
12-month price target
65,57
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
8 analysts · indicative
Ownership
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability
-28,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HROW.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to HROW.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Harrow Inc. operates in the Health Care sector, specifically within the Pharmaceuticals industry, generating revenue through its disclosed business activities.

    Classification85 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    Harrow Inc. maintains a capital structure characterized by high leverage, with long-term debt of $250.0 million against total equity of $52.4 million, resulting in a debt-to-equity ratio of 4.77. The company holds $72.9 million in cash and equivalents, leading to a negative net cash position after subtracting total debt. Liquidity is assessed as medium risk, supported by a current ratio that is not explicitly provided but implied by the balance sheet composition. The market capitalization stands at $1.46 billion, reflecting a price-to-book ratio of 28.01 and an EV/Revenue multiple of 6.09.

    Profitability metrics indicate operational challenges, with a net income of -$5.1 million and an operating income of $30.5 million on revenues of $272.3 million. The return on equity is -28.53%, and the return on assets is -3.75%, signaling negative returns on invested capital. Gross profit is $204.4 million, suggesting a gross margin of approximately 75%, which is typical for pharmaceutical companies, but operating expenses erode this advantage. Without cohort median data, direct comparison to industry peers is omitted, but the negative net income contrasts with the positive operating cash flow of $43.9 million.

    Revenue concentration by segment or geography is not disclosed in the available data. The company’s total revenue of $272.3 million is attributed to its overall operations without further breakdown.

    Growth trajectory analysis is limited due to the absence of historical period data. The current revenue figure of $272.3 million serves as the baseline for future projections.

    Risk factors include medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, highlighting leverage concerns. The high debt-to-equity ratio of 4.77 further underscores financial leverage risks.

    Recent events include analyst estimates with a mean price target of $65.57 and a median price target of $60.00, indicating positive market sentiment. The mean recommendation is 1.62, with 3 strong buys and 5 buys, and no holds. News observations indicate reconciler enqueue events for analysis jobs, but no specific corporate actions or news events are detailed.

    Key takeaways
    • High leverage with a debt-to-equity ratio of 4.77 and negative net cash position.
    • Negative profitability with a net income of -$5.1 million and ROE of -28.53%.
    • Strong analyst sentiment with a mean price target of $65.57 and 1.62 recommendation.
    • Positive operating cash flow of $43.9 million despite net losses.
    • Low dilution risk but medium liquidity risk.
    • "margin_outlook_rationale": "Gross margins are strong at ~75%, but operating margins are pressured by high expenses, leading to net losses.",

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-11
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $44.2M, −7,6% YoY; Operating income −96,6% YoY.

    Revenue$44.2M−7,6 % YoY
    Operating income-$22.1M−96,6 % YoY
    Net income-$27.6M−55,2 % YoY
    Free cash flow-$40.2M−203,3 % YoY
    EPS
    Operating cash flow-$9.0M−145,7 % YoY
    Financials
    Income statement
    Revenue$44.2M
    Gross profit$27.0M
    Operating income-$22.1M
    Net income-$27.6M
    Margins
    Gross margin61.2%
    Operating margin-50.0%
    Net margin-62.4%
    FCF margin-91.0%
    Balance sheet
    Total assets$419.5M
    Total liabilities$390.8M
    Total equity$28.7M
    Cash & equivalents$94.6M
    Long-term debt$292.1M
    Cash flow
    Operating cash flow-$9.0M
    CapEx-$18.2M
    Free cash flow-$40.2M
    SBC
    P&L flow · revenue → net income
    Revenue $44.2MOperating costs $66.3MTax $5.5MNet income $27.6M
    Highlights
    • Revenue $44.2M, −7,6% YoY
    • Operating income −96,6% YoY
    • Net income −55,2% YoY
    • Free cash flow −203,3% YoY
    • Net margin -62.4%

    Valuation TTM

    Market price
    $39,09
    Market cap
    $1.46B
    Enterprise value
    $1.64B
    P/E
    Non-GAAP P/E
    EV / Revenue
    6.1x
    EV / Op income
    137.3x
    EV / OCF
    37.3x
    P / B
    28.0x
    P / Tangible book
    28.0x
    Tangible book
    $52.1M
    Net cash
    -$177.1M
    Current ratio
    Debt / equity
    4.8
    ROA
    -3.8%
    ROE
    -28.5%
    Cash conversion
    -293.0%
    CapEx / revenue
    -0.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships16 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries16
    EX21:0109e43fd7f9EX21:0109e43fd7f9Subsidiarie97%
    EX21:0ff8b92f276cEX21:0ff8b92f276cSubsidiarie97%Source ↗
    EX21:154f50a84ce6EX21:154f50a84ce6Subsidiarie97%
    EX21:2d289d0ba3b0EX21:2d289d0ba3b0Subsidiarie97%
    EX21:335cd93d3ef7EX21:335cd93d3ef7Subsidiarie97%Source ↗
    EX21:364d655f3a73EX21:364d655f3a73Subsidiarie97%Source ↗
    EX21:3dfa0008420bEX21:3dfa0008420bSubsidiarie97%
    EX21:47c215b5f70eEX21:47c215b5f70eSubsidiarie97%Source ↗
    EX21:4ae04d01a46dEX21:4ae04d01a46dSubsidiarie97%
    EX21:4ba69735ca53EX21:4ba69735ca53Subsidiarie97%Source ↗
    EX21:5184a1cdb19aEX21:5184a1cdb19aSubsidiarie97%Source ↗
    EX21:9003b6e28c3cEX21:9003b6e28c3cSubsidiarie97%
    EX21:a44a834ea620EX21:a44a834ea620Subsidiarie97%
    EX21:af45b9700bb0EX21:af45b9700bb0Subsidiarie97%Source ↗
    EX21:d1fee3a14663EX21:d1fee3a14663Subsidiarie97%Source ↗
    EX21:e9fb9ad9ddf2EX21:e9fb9ad9ddf2Subsidiarie97%Source ↗

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,23
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    8
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-29 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,23
    Revenueno estimateno estimate348,5M USD
    Operating incomeno estimateno estimate38,9M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy3
    Buy5
    Hold0
    Sell0
    Strong sell0
    12-month price target$65,57 · Median $60,00
    Low $59,00High $88,00
    Operating income · consensus38,9M USD
    EPS surprise
    −160,2 %
    reported vs consensus · miss
    Revenue surprise
    −21,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$59,00
    Mean$65,57
    Median$60,00
    High$88,00
    Spot$39,09
    +67.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin4,4 %Below median
    Net Margin-5,6 %Below median
    ROE-28,5 %Bottom quartile
    Capex / Rev-0,4 %Above P75
    D/E4,77Bottom quartile
    Cash Conv-2,93Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 144 256 sh2 exercises · 7 grants8 insiders
    • Graves Adrienne LDirector · RSU → Common StockAcquired 5 248grant · 2026-06-18
    • Sternberg Perry J.Director · RSU → Common StockAcquired 5 248grant · 2026-06-18
    • SILVERNAIL LAUREN PDirector · RSU → Common StockAcquired 5 248grant · 2026-06-18
    • Shojaei AmirCHIEF SCIENTIFIC OFFICER · Restricted Stock Units → Common StockAcquired 10 000grant · 2026-05-15
    • Sullivan Patrick WilliamCHIEF COMMERCIAL OFFICER · RSU → Common StockAcquired 15 000grant · 2026-01-30
    • Sullivan Patrick WilliamCHIEF COMMERCIAL OFFICER · RSU → Common StockAcquired 25 000grant · 2026-01-30
    • BAUM MARK LDirector, CHIEF EXECUTIVE OFFICER · Stock Option (Right to Buy) → Common StockDisposed 180 000 @ $3,95exercise · 2025-12-12
    • BOLL ANDREW R.PRESIDENT AND CFO · Stock Option (Right to Buy) → Common StockDisposed 60 000 @ $3,95exercise · 2025-12-12
    • Pollard Randall E.CHIEF ACCOUNTING OFFICER · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $39,00grant · 2025-09-01

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Harrow, Inc. Market data — financials · 2026-07-29
    • reconciler_enqueue (reconciler) on HROW.O · 2026-07-29
    • Harrow Inc Market data — analyst estimates · 2026-07-29
    • Harrow Inc Market data — ESG · 2026-07-29
    • HROW.O HA canonical relationships · 2026-07-29

    Ownership & reference

    Top holders

    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$20M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$5M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$30M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$12M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$10M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$10M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$94M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$4M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$30M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$45M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$2M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$3M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$3M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$5M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Mark L. BaumChairman of the Board, Chief Executive Officer

    Insider activity

    Net selling4 buys · 6 sellsnet -$8,7M5 insiders · last 365d
    • Graves Adrienne LDirector · Common StockBought 1 000 @ $31,07$31K · 2026-05-18
    • SILVERNAIL LAUREN PDirector · Common StockBought 1 000 @ $31,00$31K · 2026-05-18
    • BAUM MARK LDirector, CHIEF EXECUTIVE OFFICER · Common StockBought 10 000 @ $30,20$302K · 2026-05-14
    • BOLL ANDREW R.PRESIDENT AND CFO · Common StockBought 3 500 @ $29,90$105K · 2026-05-14
    • Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 134 000 @ $39,67$5,3M · 2026-03-04
    • Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 4 263 @ $39,67$169K · 2026-03-04
    • Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 1 309 @ $39,15$51K · 2026-03-03
    • Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 59 000 @ $39,15$2,3M · 2026-03-03
    • Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 5 000 @ $54,18$271K · 2026-02-27
    • Opaleye Management Inc.10% owner · Common Stock, par value $0.001 per shareSold 20 000 @ $53,35$1,1M · 2026-01-06
    • BOLL ANDREW R.PRESIDENT AND CFO · Common StockOther 60 000 @ $3,95$237K · 2025-12-12
    • BAUM MARK LDirector, CHIEF EXECUTIVE OFFICER · Common StockOther 79 994 @ $47,06$3,8M · 2025-12-12
    • BAUM MARK LDirector, CHIEF EXECUTIVE OFFICER · Common StockOther 180 000 @ $3,95$711K · 2025-12-12
    • BOLL ANDREW R.PRESIDENT AND CFO · Common StockOther 26 665 @ $47,06$1,3M · 2025-12-12

    Short positioning

    6.8Mshares short-4.3% vs prior
    12.62days to cover
    71.2%short of daily vol
    2fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HROW.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    HROWEX21:010EX21:0ffEX21:154EX21:2d2EX21:335EX21:364EX21:3dfEX21:47cEX21:4aeEX21:4baPharmaceutical
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Total assets (annual): USD 399.48MUnknown
    • Gross profit (annual): USD 204.37MUnknown
    • Cost of revenue (annual): USD 67.93MUnknown
    • Operating cash flow (annual): USD 43.86MUnknown
    • Total operating expenses (annual): USD 173.85MUnknown
    • Current assets (annual): USD 211.75MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -0Unknown
    • Current liabilities (annual): USD 96.3MUnknown
    • Pre-tax income (annual): USD -1.37MUnknown
    • Total liabilities (annual): USD 347.39MUnknown
    • Shareholders' equity (annual): USD 52.45MUnknown
    • Shares outstanding (annual): 37.23MUnknown
    • Cash & equivalents (annual): USD 72.93MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -0Unknown
    • R&D expense (annual): USD 20.94MUnknown
    • Capex (annual): USD 887KUnknown
    • Operating income (annual): USD 30.52MUnknown
    • Revenue (annual): USD 272.3MUnknown
    • Net income (annual): USD -5.14MUnknown
    • Long-term debt (annual): USD 250MUnknown
    • Shares outstanding (annual): 35.62MUnknown
    • Current liabilities (annual): USD 91.34MUnknown
    • Operating income (annual): USD 8.82MUnknown
    • Total operating expenses (annual): USD 141.55MUnknown
    Showing 24 of 38 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-18 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative
    2026-06-18 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative
    2026-06-18INSIDERSILVERNAIL LAUREN P acquired 5.2k sh RSU — Director
    2026-06-18INSIDERSternberg Perry J. acquired 5.2k sh RSU — Director
    2026-06-18INSIDERGraves Adrienne L acquired 5.2k sh RSU — Director
    2026-06-03FILING8-K filing →
    2026-05-18 00:00 UTCINSIDER5 insider transactions — 2026-05 · net buy $469k 1 derivative
    2026-05-18 00:00 UTCINSIDER5 insider transactions — 2026-05 · net buy $469k 1 derivative
    2026-05-18INSIDERGraves Adrienne L bought 1.0k sh — Director ~$31k
    2026-05-18INSIDERSILVERNAIL LAUREN P bought 1.0k sh — Director ~$31k
    2026-05-15INSIDERShojaei Amir acquired 10.0k sh Restricted Stock Units — CHIEF SCIENTIFIC OFFICER
    2026-05-14INSIDERBAUM MARK L bought 10.0k sh — Director, CHIEF EXECUTIVE OFFICER ~$302k
    2026-05-14INSIDERBOLL ANDREW R. bought 3.5k sh — PRESIDENT AND CFO ~$105k
    2026-05-11 16:05 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 44.2M · Net USD -27.6M
    2026-05-11FILING10-Q filing →
    2026-05-11FILING8-K filing →
    2026-04-24FILINGDEF 14A filing →
    2026-03-27FILING8-K filing →
    2026-03-24FILING8-K filing →
    2026-03-24FILING8-K filing →
    2026-03-10FILING8-K filing →
    2026-03-04 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $7.8M
    2026-03-04 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $7.8M
    2026-03-04INSIDEROpaleye Management Inc. sold 134.0k sh Common Stock, par value $0.001 per share — 10% owner ~$5.32M
    2026-03-04INSIDEROpaleye Management Inc. sold 4.3k sh Common Stock, par value $0.001 per share — 10% owner ~$169k
    2026-03-03INSIDEROpaleye Management Inc. sold 1.3k sh Common Stock, par value $0.001 per share — 10% owner ~$51k
    2026-03-03INSIDEROpaleye Management Inc. sold 59.0k sh Common Stock, par value $0.001 per share — 10% owner ~$2.31M
    2026-03-02 16:05 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 89.1M · Net USD 6.6M
    2026-03-02 16:05 UTCEARNINGSAnnual results — FY 2026 Revenue USD 272.3M · Net USD -5.1M
    2026-03-02FILING10-K filing →
    2026-03-02FILING8-K filing →
    2026-02-27 00:00 UTCINSIDER1 insider transaction — 2026-02 · net sell $271k
    2026-02-27 00:00 UTCINSIDER1 insider transaction — 2026-02 · net sell $271k
    2026-02-27INSIDEROpaleye Management Inc. sold 5.0k sh Common Stock, par value $0.001 per share — 10% owner ~$271k
    2026-02-02FILING8-K filing →
    2026-01-30INSIDERSullivan Patrick William acquired 15.0k sh RSU — CHIEF COMMERCIAL OFFICER
    2026-01-30INSIDERSullivan Patrick William acquired 25.0k sh RSU — CHIEF COMMERCIAL OFFICER
    2026-01-06INSIDEROpaleye Management Inc. sold 20.0k sh Common Stock, par value $0.001 per share — 10% owner ~$1.07M
    2025-12-12INSIDERBOLL ANDREW R. transacted 60.0k sh — PRESIDENT AND CFO ~$237k
    Showing the 40 most recent of 57 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage